On January 23, 2014 Sun Pharma Advanced Research Company reported that it has received the approval of the Drug Controller General of India (DGCI) for its medicine for treatment of breast cancer (Press release, Sun Pharma Advanced Research, JAN 23, 2014, View Source [SID1234556401]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The medicine, Paclitaxel Injection Concentrate for Nanodispersion (PICN), was found to be equally effective and safe when compared to Abraxane in a clinical study in metastatic breast cancer patients, the company said in a statement.

"PICN is approved in India for both the 260mg/m2 and 95mg/m2 doses to be administered every 3 weeks," it said, adding, the medicine offers the convenience of a quick and easy one-step dilution and infusion preparation for healthcare professionals.

PICN can be administered in a short 30 minute infusion and unlike conventional Paclitaxel formulations it does not require pre-medication with steroids and anti-histamines and does not lead to any significant hypersensitivity reaction in patients.